The primary growth driver of the worldwide osteoarthritis treatment market is the introduction of novel, affordable drugs for the treatment of osteoarthritis. Tanezumab, a medication jointly created by Pfizer and Eli Lily in 2017 for the treatment of osteoarthritis-related chronic lower back pain, is pending FDA approval and is anticipated to benefit several millions of patients. Other factors influencing the growth of the worldwide osteoarthritis treatment market include obesity, an increase in orthopaedic injuries, crystal deposition, old age, joint damage, an increase in pipeline medications, and rising public awareness. There are about 100 different forms of arthritis, with osteoarthritis being the most prevalent variety, according to the Centres for Disease Control and Prevention in 2016. The Arthritis Foundation also states that in 2015, out of the 54.4 million people with arthritis in the U.S., 30.8 million of them had osteoarthritis. The major participants in the worldwide osteoarthritis treatment market have direct growth prospects due to these important statistics.
According to Coherent Market Insights, The market for treating Osteoarthritis was estimated to be worth USD 7.40 billion in 2021 and is anticipated to expand at a CAGR of 8.5% over the next five years.
Leading Companies in the Osteoarthritis Treatment Industry:
1. Novartis AG
The business was established in March 1996 and has offices in Basel, Switzerland, and Cambridge, Massachusetts, in the US. Novartis provides coverage for all types of medications, including authorization, over-the-counter, immunisations, diagnostics, eyewear, and veterinary care. Through its firms, Novartis engages in a number of direct activities, including managing, advertising, operations, and research.
2. Pfizer Inc.
The firm was stareted in 1849, and Manhattan, New York City, serves as its headquarters. For the medical specialities of immunology, cancer, heart, endocrinology, and neurology, Pfizer discovers and produces drugs and vaccines. Pfizer purchased Amplyx Pharmaceuticals in April 2021, along with the antifungal drug fosmanogepix (APX001The business successfully acquired Biohaven Pharma in October 2022, together with its calcitonin gene-related peptide programmes.
3. Abbott Laboratories
Chicago, Illinois serves as the company's US headquarters. It was founded there in 1888. It offers brand-name generic medications, nutritional goods, medical supplies, and diagnostics. Abbott unveiled its Lingo line of consumer biowearable sensors in January 2022. To optimise food and exercise regimens, Lingo collects a range of biological measurements. In August 2022, the FDA approved Abbott's Proclaim Plus, a multipurpose spinal cord stimulation device for treating chronic pain.
